BTIG analyst Mark Massaro raised the firm’s price target on Castle Biosciences (CSTL) to $50 from $38 and keeps a Buy rating on the shares as part of a broader research note reviewing 2025 for Diagnostics and Tools. The firm is also positive on the stock’s risk-reward, adding that at 2.6-times sales, the stock has a best-in-class financial profile, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences announces publication of new SRMA on TissueCypher
- Castle announces publication of consensus paper on DecisionDx-Melanoma test
- Castle Biosciences announces new data on DecisionDx-Melanoma test
- Castle Biosciences: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Castle Biosciences Navigates Regulatory Uncertainty Amid Shifting Policies and Trade Challenges